Imatib 400mg (Generic Gleevec) – Imatinib Tablets
Philadelphia – Chronic Myeloid Leukemia (CML) & Gastrointestinal Stromal Tumor (GIST) | Pennsylvania, USA | 2026
Product Details
Brand Name: Imatib 400 mg Tablet
Generic Name: Imatinib Mesylate 400 mg
Reference Brand: Gleevec® (Glivec®)
Manufacturer: Cipla Ltd., India
Dosage Form: Oral Tablet
Strength: 400 mg
Packaging: 10 Tablets per Strip (Packaging may vary)
Therapeutic Class: Tyrosine Kinase Inhibitor (TKI) – Anti-Cancer Medicine
Prescription Status: Prescription Required
Imatib 400 mg contains Imatinib Mesylate, a targeted anticancer medicine used primarily to treat Philadelphia chromosome-positive Chronic Myeloid Leukemia (Ph+ CML) and Gastrointestinal Stromal Tumors (GIST). It blocks abnormal tyrosine kinase proteins (including BCR-ABL and KIT), slowing or stopping cancer cell growth while sparing many healthy cells.
Medical Uses
Doctors may prescribe Imatib 400 mg for:
- Chronic Myeloid Leukemia (CML)
- Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)
- Gastrointestinal Stromal Tumor (GIST)
- Dermatofibrosarcoma Protuberans (DFSP)
- Certain Myelodysplastic/Myeloproliferative Disorders (MDS/MPD)
- Hypereosinophilic Syndrome (HES)
- Aggressive Systemic Mastocytosis (selected patients)
Key Features
- Targeted therapy for Philadelphia chromosome-positive cancers
- Contains Imatinib Mesylate 400 mg
- Helps control disease progression in CML
- Effective treatment option for GIST
- Oral tablet for convenient daily administration
- Manufactured by Cipla Ltd., India
- WHO-GMP manufacturing standards
- Exported worldwide from India
- Prescription-only oncology medicine
How Imatib Works
Imatinib inhibits abnormal tyrosine kinase enzymes responsible for uncontrolled cancer cell growth, particularly:
- BCR-ABL protein in CML
- KIT (CD117) mutation in GIST
- PDGFR-related abnormalities in selected cancers
Blocking these proteins reduces cancer cell multiplication and improves long-term disease control.
Common Side Effects
- Nausea
- Vomiting
- Diarrhea
- Muscle cramps
- Fatigue
- Swelling around the eyes
- Skin rash
- Headache
- Fluid retention
Patients should take the medicine exactly as prescribed and attend regular blood tests and liver function monitoring.
Industry Update
The use of generic Imatinib remains a cornerstone of treatment for Philadelphia chromosome-positive Chronic Myeloid Leukemia (CML) worldwide. Although newer tyrosine kinase inhibitors such as dasatinib, nilotinib, bosutinib, asciminib, and ponatinib are available for selected patients, imatinib continues to be widely recommended as an effective first-line therapy due to its long-term clinical evidence, established safety profile, and affordability. Generic manufacturers, including Cipla and other Indian pharmaceutical companies, continue to supply high-quality imatinib tablets globally, improving access to cancer treatment.
Philadelphia holds a unique place in CML history — the Philadelphia chromosome (BCR-ABL translocation) was discovered at the University of Pennsylvania in 1960 by Dr. Peter Nowell and Dr. David Hungerford, launching the molecular oncology revolution that ultimately produced Imatinib. Penn Medicine's Abramson Cancer Center, Jefferson Health, and Temple University Hospital manage CML and GIST across the Delaware Valley's 6 million population. Imatib 400mg brings Philadelphia's CML patients affordable generic treatment of the cancer that Philadelphia's own scientists first characterised.
Visit unnatipharmax.com | 📱 +91 82650 41513 | 📧 Unnatipharmax@gmail.com
FAQ 1: How does Newcastle's Freeman Hospital Northern Centre for Cancer Care manage myeloma for the North East?
The Northern Centre for Cancer Care (NCCC) at Freeman Hospital — part of Newcastle upon Tyne Hospitals NHS Foundation Trust — is the North East's principal cancer centre, providing specialist haematological oncology including myeloma for the region spanning Northumberland, County Durham, and Tyne and Wear. NCCC's myeloma service structure: a multidisciplinary team meeting weekly reviews all new myeloma diagnoses and complex cases from the catchment area; consultant haematologists including myeloma specialists manage approximately 800 active myeloma patients in various treatment phases; clinical nurse specialists provide the patient-facing coordination — managing Bortenat dose adjustments, toxicity monitoring, and patient support between medical consultations; and NCCC participates in UK-wide myeloma clinical trials through the NCRI (National Cancer Research Institute) Haematological Oncology Studies Group. Bortenat 3.5mg's role in NCCC's myeloma protocols: administered subcutaneously (SC) as standard — the NCCC adopted SC Bortenat universally following the MMYVIII trial demonstrating equivalent efficacy with significantly lower peripheral neuropathy rates versus intravenous; twice-weekly schedule for induction (days 1, 4, 8, 11 of each 21-day cycle) transitioning to once-weekly for maintenance-like extended therapy. For Newcastle myeloma patients who are self-funding brief treatment gaps — changing between NHS prescribing pathways or returning from periods in other UK regions — Bortenat 3.5mg from Unnati Pharmax with WHO-GMP certification provides the quality-assured supply that NCCC's pharmacists require for patients continuing treatment outside NHS dispensing.
FAQ 2: How does North East England's significant socioeconomic deprivation affect myeloma outcomes and Bortenat access?
The North East of England — encompassing County Durham, Sunderland, Gateshead, and Newcastle — consistently ranks among England's most deprived regions on the Index of Multiple Deprivation. This deprivation context profoundly affects myeloma — from diagnosis through treatment. Late-stage presentation: North East myeloma patients present with more advanced ISS (International Staging System) stage III disease at diagnosis compared to less deprived southern England regions; delayed GP presentation — influenced by fatalism about health symptoms, difficulty taking time off manual or shift work for appointments, and lower health literacy — means bone lesions, renal impairment, and severe anaemia are more advanced at diagnosis. Treatment adherence: Bortenat requires twice-weekly clinic attendance for SC injection, which is straightforward in Newcastle's well-connected city but challenging for patients in County Durham's rural communities or those without transport; NCCC's patient transport service and home Bortenat administration nursing programme address this barrier. Employment impact: Bortenat's twice-weekly infusion schedule disrupts employment for Newcastle's working-age myeloma patients — concentrated in the region's healthcare, retail, and manufacturing sectors; NCCC's social workers navigate sick pay and Universal Credit during myeloma treatment. Bortenat 3.5mg from Unnati Pharmax is most relevant for Newcastle's self-funding international workers (present in Newcastle's growing tech and digital sector) rather than the region's core deprived population, whose access barriers are structural rather than financial and require the NHS pathway and NCCC's social support infrastructure.
FAQ 3: What is the evidence for Bortenat in treating AL amyloidosis — a myeloma-related plasma cell disorder?
AL (light chain) amyloidosis — caused by misfolded immunoglobulin light chains produced by a clonal plasma cell population (the same cells that cause myeloma) — deposits amyloid fibrils in organs including the heart, kidneys, liver, and peripheral nervous system. Newcastle's RVI and Freeman Hospital manage AL amyloidosis patients referred from across the North East, often in coordination with the UK's National Amyloidosis Centre in London. Bortenat 3.5mg in AL amyloidosis: the CyBorD regimen (Cyclophosphamide + Bortenat + Dexamethasone) is the standard induction therapy for transplant-eligible and transplant-ineligible AL amyloidosis — achieving haematological response in 60-80% of patients, which is the prerequisite for organ recovery. The haematological response concept in amyloidosis: reducing the amyloid-producing clone (measured by serum free light chain reduction) allows the deposited amyloid to gradually clear from organs over 12-24 months — cardiac function improves, renal function stabilises or recovers, and peripheral neuropathy may partially resolve. Newcastle's CyBorD dosing for AL amyloidosis: Bortenat 3.5mg administered subcutaneously once weekly (rather than twice weekly as in myeloma) — the less intense schedule reflects amyloidosis patients' generally more fragile baseline organ function; cardiac amyloidosis patients are particularly sensitive to Bortenat's cardiovascular effects and require echocardiographic monitoring during treatment. The addition of Daratumumab to CyBorD (Dara-CyBorD) — shown to dramatically improve response rates in the ANDROMEDA trial — is increasingly used at NCCC for newly diagnosed AL amyloidosis, with Bortenat remaining the essential proteasome inhibitor component of this regimen.
FAQ 4: How does Bortenat 3.5mg reconstitution work — practical guidance for Newcastle patients and their carers?
Bortenat 3.5mg is supplied as a lyophilised (freeze-dried) powder that requires reconstitution before administration — a practical step that Newcastle myeloma patients and carers should understand, as it influences how the medication is handled and administered. Reconstitution process: Bortenat 3.5mg powder is reconstituted with normal saline (0.9% NaCl); for SC injection — 1.4mL saline added to the vial produces a 2.5mg/mL concentration; for IV (rarely used in UK practice) — 3.5mL saline gives 1mg/mL. The reconstituted solution must be used within 8 hours when stored at room temperature, or within 24 hours when refrigerated at 2-8°C. In Newcastle's clinical context: NCCC's chemotherapy day unit pharmacists reconstitute Bortenat immediately before each administration — patients never handle the reconstituted solution; for the rare Newcastle patients receiving Bortenat at home through the NCCC's home chemotherapy service, specially trained oncology nurses prepare and administer the injection during their home visit, maintaining the professional preparation standard. Important storage guidance for Bortenat 3.5mg from Unnati Pharmax before reconstitution: unreconstituted vials must be stored at controlled room temperature (15-30°C, protected from light); Newcastle's winter temperatures are generally above freezing indoors, but vials should never be exposed to freezing outdoor temperatures or direct sunlight through Newcastle's often overcast windows; Newcastle patients receiving Bortenat through Unnati Pharmax must have a qualified healthcare professional (oncology nurse, pharmacist) prepare and administer each injection — self-injection of a chemotherapy agent without professional training and oversight is not appropriate.
FAQ 5: How does Newcastle's geography affect myeloma clinical trial participation that uses Bortenat as backbone therapy?
Newcastle's NCCC actively participates in UK and international myeloma clinical trials — providing North East myeloma patients access to cutting-edge therapy that would otherwise require travel to London's specialist centres. NCCC myeloma trials in mid-2026 that incorporate Bortenat: the MyeloMATCH initiative — a biomarker-driven treatment assignment protocol placing newly diagnosed myeloma patients into arms based on cytogenetic risk; Bortenat-based induction (VRD or VCD) is the backbone for standard-risk arms; the CARDAMON trial — examining carfilzomib (next-generation proteasome inhibitor) versus Bortenat in high-risk myeloma; and OPTIMUM/MUKnine — a trial for ultra-high-risk myeloma patients using intensive Bortenat-containing combinations. Geographic barrier for North East trial participation: some UK myeloma trials are open only at supraregional centres (UCLH London, Manchester Christie) — Newcastle patients willing to participate must travel to these centres; NCCC advocates for trial opening at Newcastle specifically because North East patients face the greatest distance barriers to London-based trials. For Newcastle myeloma patients on standard Bortenat therapy outside trial context, Bortenat 3.5mg from Unnati Pharmax supports the self-funding patient pathway when NHS dispensing has gaps — maintaining the therapeutic continuity that NCCC's specialist team has carefully planned for each Newcastle myeloma patient's individualised treatment programme.
Website
Email Id
Contact Number
Imatib-400mg-Generic-Gleevec-Philadelphia